Biblio Discovery — Demo Discovery Service

6 results for "Jean-Philippe Adam"

Showing 1–6 · 2.36 seconds · RSS

  1. Journal Article Full text

    Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib

    Normand Blais; Jean-Philippe Adam; John Nguyen et al.

    Current Oncology, Vol. 28 No. 1 · 2021 · English · DOAJ Scopus

    The use of lorlatinib, an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive metastatic non-small cell lung cancer, is associated with dyslipidemia in over 80% of patients. Clinical trial protocols for the management of lorlatinib-associated dyslipidemia differ from…

  2. Journal Article

    Gemcitabine, dexamethasone and cisplatin with or without rituximab is highly effective as a mobilization regimen in relapsed or refractory lymphoma

    Vincent T. Taillefer; Marianne Emond; Marie-Hélène Leblanc et al.

    Leukemia Research Reports, Vol. 25 · 2026 · English · DOAJ Scopus

    Introduction: A combination of Gemcitabine, Dexamethasone and Cisplatin (GDP) with or without rituximab (±R) is an outpatient treatment widely used for relapsed or refractory (R/R) lymphoma. Limited data are available on stem cell mobilization following GDP treatment. Method: A retrospective…

  3. Journal Article

    Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab

    Fanny Zulay Acero Brand; Nicolas Suter; Jean-Philippe Adam et al.

    Journal for ImmunoTherapy of Cancer, Vol. 6 No. 1 · 2018 · English · DOAJ Scopus

    Abstract Background Pembrolizumab is an anti–programmed death 1 (PD-1) receptor monoclonal antibody that has shown activity as second line treatment for metastatic head and neck squamous cell carcinoma (HNSCC). Immune-related adverse events are now well described complications of PD-1 inhibitors…

  4. Journal Article Full text

    Successful Management of Natalizumab-Associated Primary Central Nervous System Lymphoma through Autologous Stem Cell Transplant

    Karine Moineau-Vallée; Justine Rinfret; My Hanh Luu Hoai et al.

    Current Oncology, Vol. 28 No. 1 · 2020 · English · DOAJ Scopus

    Natalizumab is used as a second-line treatment for multiple sclerosis (MS). Some reports have linked natalizumab to primary central nervous system lymphoma (PCNSL), although few have described its management. A 45-year-old woman with Balo’s Concentric Sclerosis presented dizziness, vertigo…

  5. Journal Article

    Intraductal papillary mucinous neoplasms of the pancreas and European guidelines: importance of the surgery type in the decision-making process

    Etienne Buscail; Thomas Cauvin; Benjamin Fernandez et al.

    BMC Surgery, Vol. 19 No. 1 · 2019 · English · DOAJ Scopus

    Abstract Background The European Consensus 2018 established a new algorithm with absolute and relative criteria for intraductal papillary mucinous neoplasms of the pancreas (IPMN) management. The aim of this study was to validate these criteria and analyse the outcomes in function of the surgical…

  6. Journal Article

    Evaluation of postoperative ascites after somatostatin infusion following hepatectomy for hepatocellular carcinoma by laparotomy: a multicenter randomized double-blind controlled trial (SOMAPROTECT)

    Kayvan Mohkam; Michel Rayar; Jean-Philippe Adam et al.

    BMC Cancer, Vol. 18 No. 1 · 2018 · English · DOAJ Scopus

    Abstract Background The majority of patients undergoing hepatectomy for hepatocellular carcinoma (HCC) suffer from underlying liver disease and are exposed to the risk of postoperative ascites, which is favored by an imbalance between portal venous inflow and a diminished hepatic volume. Finding a…